MedElevator
Войти в исследования The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2026
Cenobamate for Status Epilepticus: A Systematic Review.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mo Moses, Howard Anna, Jaworska Natalia, Bencsik Caralyn, Bains Ish, Kromm Julie Anne
Аннотация
BACKGROUND: Status epilepticus (SE) is a neurologic emergency characterized by prolonged or recurrent seizures leading to significant secondary brain injury, complications, morbidity and mortality. Timely and aggressive management is paramount to mitigate this disease burden, but response rates to first- and second-line antiseizure medications (ASMs) remain suboptimal. Cenobamate (CBM), a novel ASM, has shown great promise in clinical trials as an adjunctive agent for patients with refractory focal epilepsy, but little is known about its efficacy and safety for SE.
OBJECTIVE: This systematic review aims to evaluate the efficacy and safety of CBM for managing SE, refractory SE and super-refractory SE (SRSE).
METHODS: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. A literature search was conducted across MEDLINE, EMBASE, CINAHL and Cochrane CENTRAL. Original research involving adult patients with SE treated with CBM were included, and study quality was assessed. Data on patient demographics, treatment protocols and outcomes were extracted.
RESULTS: Of 62 articles screened, 4 studies met the inclusion criteria, comprising 2 full manuscripts and 2 conference abstracts. A total of five patients with SRSE were treated with CBM. Seizure cessation was observed in two patients (40%). Reported adverse events included somnolence and gastrointestinal disturbances.
CONCLUSIONS: Evidence supporting the use of CBM for the management of patients with SE is limited. Further structured studies are needed to establish optimal dosing, efficacy and safety of CBM for patients with SE.
OBJECTIVE: This systematic review aims to evaluate the efficacy and safety of CBM for managing SE, refractory SE and super-refractory SE (SRSE).
METHODS: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. A literature search was conducted across MEDLINE, EMBASE, CINAHL and Cochrane CENTRAL. Original research involving adult patients with SE treated with CBM were included, and study quality was assessed. Data on patient demographics, treatment protocols and outcomes were extracted.
RESULTS: Of 62 articles screened, 4 studies met the inclusion criteria, comprising 2 full manuscripts and 2 conference abstracts. A total of five patients with SRSE were treated with CBM. Seizure cessation was observed in two patients (40%). Reported adverse events included somnolence and gastrointestinal disturbances.
CONCLUSIONS: Evidence supporting the use of CBM for the management of patients with SE is limited. Further structured studies are needed to establish optimal dosing, efficacy and safety of CBM for patients with SE.